Yüklüyor......
Hypomethylating agent combination strategies in myelodysplastic syndromes: Hopes and shortcomings
The hypomethylating agents (HMA) azacitidine and decitabine are both approved by the FDA for the treatment of myelodysplastic syndromes (MDS). Although heralded as a significant advancement, HMA lead to responses in less than half of patients and for those that respond most will relapse. As such, th...
Kaydedildi:
| Yayımlandı: | Leuk Lymphoma |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5785935/ https://ncbi.nlm.nih.gov/pubmed/27654579 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2016.1228927 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|